{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T16:09:43Z","timestamp":1793722183419,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1038\/s41591-021-01489-1","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T16:12:33Z","timestamp":1633968753000},"page":"1836-1848","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":217,"title":["ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials"],"prefix":"10.1038","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6577-5657","authenticated-orcid":false,"given":"Roberto A.","family":"Calle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeta B.","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santos","family":"Carvajal-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trenton T.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeepta","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Rinaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Mancuso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naresh","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Somayaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Inglot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0170-3974","authenticated-orcid":false,"given":"Theresa A.","family":"Tuthill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kou","family":"Kou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magalie","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Tesz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dullea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5879-4726","authenticated-orcid":false,"given":"Kendra K.","family":"Bence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5269-2155","authenticated-orcid":false,"given":"Albert M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Pfefferkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4783-8620","authenticated-orcid":false,"given":"William P.","family":"Esler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"1489_CR1","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani, N. et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67, 328\u2013357 (2018).","journal-title":"Hepatology"},{"key":"1489_CR2","first-page":"1388","volume":"64","author":"EASL-EASD-EASO.","year":"2016","unstructured":"EASL-EASD-EASO. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol. 64, 1388\u20131402 (2016).","journal-title":"J. Hepatol."},{"key":"1489_CR3","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1111\/j.1572-0241.1999.01377.x","volume":"94","author":"EM Brunt","year":"1999","unstructured":"Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A. & Bacon, B. R. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 94, 2467\u20132474 (1999).","journal-title":"Am. J. Gastroenterol."},{"key":"1489_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cld.2015.10.010","volume":"20","author":"A Marengo","year":"2016","unstructured":"Marengo, A., Jouness, R. I. & Bugianesi, E. Progression and natural history of nonalcoholic fatty liver disease in adults. Clin. Liver. Dis. 20, 313\u2013324 (2016).","journal-title":"Clin. Liver. Dis."},{"key":"1489_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","volume":"7","author":"N Rafiq","year":"2009","unstructured":"Rafiq, N. et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7, 234\u2013238 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1489_CR6","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1053\/j.gastro.2013.11.049","volume":"146","author":"JE Lambert","year":"2014","unstructured":"Lambert, J. E., Ramos-Roman, M. A., Browning, J. D. & Parks, E. J. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146, 726\u2013735 (2014).","journal-title":"Gastroenterology"},{"key":"1489_CR7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","volume":"103","author":"JK Dowman","year":"2010","unstructured":"Dowman, J. K., Tomlinson, J. W. & Newsome, P. N. Pathogenesis of non-alcoholic fatty liver disease. QJM 103, 71\u201383 (2010).","journal-title":"QJM"},{"key":"1489_CR8","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jcmgh.2019.04.007","volume":"8","author":"WP Esler","year":"2019","unstructured":"Esler, W. P. & Bence, K. K. Metabolic targets in nonalcoholic fatty liver disease. Cell. Mol. Gastroenterol. Hepatol. 8, 247\u2013267 (2019).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"1489_CR9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1146\/annurev.nutr.28.061807.155434","volume":"28","author":"D Saggerson","year":"2008","unstructured":"Saggerson, D. Malonyl-CoA, a key signaling molecule in mammalian cells. Annu. Rev. Nutr. 28, 253\u2013272 (2008).","journal-title":"Annu. Rev. Nutr."},{"key":"1489_CR10","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1073\/pnas.97.4.1444","volume":"97","author":"L Abu-Elheiga","year":"2000","unstructured":"Abu-Elheiga, L. et al. The subcellular localization of acetyl-CoA carboxylase 2. Proc. Natl Acad. Sci. USA 97, 1444\u20131449 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1489_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1432-1033.1997.00001.x","volume":"244","author":"JD McGarry","year":"1997","unstructured":"McGarry, J. D. & Brown, N. F. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244, 1\u201314 (1997).","journal-title":"Eur. J. Biochem."},{"key":"1489_CR12","doi-asserted-by":"publisher","first-page":"37099","DOI":"10.1074\/jbc.M304481200","volume":"278","author":"HJ Harwood Jr.","year":"2003","unstructured":"Harwood, H. J. Jr. et al. Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J. Biol. Chem. 278, 37099\u201337111 (2003).","journal-title":"J. Biol. Chem."},{"key":"1489_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.jcmgh.2020.06.001","volume":"10","author":"TT Ross","year":"2020","unstructured":"Ross, T. T. et al. Acetyl-CoA carboxylase inhibition improves multiple dimensions of NASH pathogenesis in model systems. Cell. Mol. Gastroenterol. Hepatol. 10, 829\u2013851 (2020).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"1489_CR14","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1002\/hep.29246","volume":"66","author":"K Stiede","year":"2017","unstructured":"Stiede, K. et al. Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: a randomized, double-blind, crossover study. Hepatology 66, 324\u2013334 (2017).","journal-title":"Hepatology"},{"key":"1489_CR15","doi-asserted-by":"publisher","first-page":"10512","DOI":"10.1021\/jm5016022","volume":"57","author":"DA Griffith","year":"2014","unstructured":"Griffith, D. A. et al. Decreasing the rate of metabolic ketone reduction in the discovery of a clinical acetyl-CoA carboxylase inhibitor for the treatment of diabetes. J. Med. Chem. 57, 10512\u201310526 (2014).","journal-title":"J. Med. Chem."},{"key":"1489_CR16","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1053\/j.gastro.2018.07.027","volume":"155","author":"R Loomba","year":"2018","unstructured":"Loomba, R. et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology 155, 1463\u20131473 (2018).","journal-title":"Gastroenterology"},{"key":"1489_CR17","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.cmet.2017.07.009","volume":"26","author":"CW Kim","year":"2017","unstructured":"Kim, C. W. et al. Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation. Cell. Metab. 26, 394\u2013406 (2017).","journal-title":"Cell. Metab."},{"key":"1489_CR18","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1002\/hep.30097","volume":"68","author":"L Goedeke","year":"2018","unstructured":"Goedeke, L. et al. Acetyl-CoA carboxylase inhibition reverses NAFLD and hepatic insulin resistance but promotes hypertriglyceridemia in rodents. Hepatology 68, 2197\u20132211 (2018).","journal-title":"Hepatology"},{"key":"1489_CR19","doi-asserted-by":"publisher","first-page":"22678","DOI":"10.1074\/jbc.M704213200","volume":"282","author":"CS Choi","year":"2007","unstructured":"Choi, C. S. et al. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance. J. Biol. Chem. 282, 22678\u201322688 (2007).","journal-title":"J. Biol. Chem."},{"key":"1489_CR20","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/hep.20783","volume":"42","author":"XX Yu","year":"2005","unstructured":"Yu, X. X. et al. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42, 362\u2013371 (2005).","journal-title":"Hepatology"},{"key":"1489_CR21","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1194\/jlr.R800018-JLR200","volume":"49","author":"CL Yen","year":"2008","unstructured":"Yen, C. L., Stone, S. J., Koliwad, S., Harris, C. & Farese, R. V. Jr. Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis. J. Lipid Res. 49, 2283\u20132301 (2008).","journal-title":"J. Lipid Res."},{"key":"1489_CR22","doi-asserted-by":"publisher","first-page":"eaav9701","DOI":"10.1126\/scitranslmed.aav9701","volume":"11","author":"NB Amin","year":"2019","unstructured":"Amin, N. B. et al. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci. Transl. Med. 11, eaav9701 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1489_CR23","first-page":"1260A","volume":"70","author":"A Saxena","year":"2019","unstructured":"Saxena, A., Chidsey, K., Somayaji, V., Ogden, A. & Duvvuri, S. Diacylglycerol acyltransferase 2 (DGAT2) inhibitor PF-06865571 reduces liver fat by MRI\u2013PDFF after 2 weeks in adults with NAFLD. Hepatology 70, 1260A (2019).","journal-title":"Hepatology"},{"key":"1489_CR24","doi-asserted-by":"publisher","first-page":"e67","DOI":"10.1016\/S0618-8278(19)30118-5","volume":"70","author":"R Loomba","year":"2019","unstructured":"Loomba, R. et al. An international, randomized, placebo-controlled phase 2 trial demonstrates novel effects of DGAT2 antisense inhibition in reducing steatosis without causing hypertriglyceridemia in T2DM patients. J. Hepatol. 70, e67\u2013e68 (2019).","journal-title":"J. Hepatol."},{"key":"1489_CR25","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M. & Sanyal, A. J. Mechanisms of NAFLD development and therapeutic strategies. Nat. Med. 24, 908\u2013922 (2018).","journal-title":"Nat. Med."},{"key":"1489_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.phrs.2018.07.014","volume":"134","author":"S Fiorucci","year":"2018","unstructured":"Fiorucci, S., Biagioli, M. & Distrutti, E. Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol. Res. 134, 289\u2013298 (2018).","journal-title":"Pharmacol. Res."},{"key":"1489_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams, L. A. et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113\u2013121 (2005).","journal-title":"Gastroenterology"},{"key":"1489_CR28","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt, M. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61, 1547\u20131554 (2015).","journal-title":"Hepatology"},{"key":"1489_CR29","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2020.04.037","volume":"73","author":"J Bates","year":"2020","unstructured":"Bates, J. et al. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation. J. Hepatol. 73, 896\u2013905 (2020).","journal-title":"J. Hepatol."},{"key":"1489_CR30","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1038\/s42255-020-00272-9","volume":"2","author":"KL Kelly","year":"2020","unstructured":"Kelly, K. L. et al. De novo lipogenesis is essential for platelet production in humans. Nat. Metab. 2, 1163\u20131178 (2020).","journal-title":"Nat. Metab."},{"key":"1489_CR31","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/j.cgh.2018.04.042","volume":"16","author":"EJ Lawitz","year":"2018","unstructured":"Lawitz, E. J. et al. Acetyl-CoA carboxylase inhibitor GS-0976 for 12 weeks reduces hepatic de novo lipogenesis and steatosis in patients with nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol. 16, 1983\u20131991 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1489_CR32","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1002\/hep.31420","volume":"73","author":"ZM Younossi","year":"2020","unstructured":"Younossi, Z. M. et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology 73, 1194\u20131198 (2020).","journal-title":"Hepatology"},{"key":"1489_CR33","first-page":"31220","volume":"31","author":"JG Stine","year":"2020","unstructured":"Stine, J. G. et al. Change in MRI\u2013PDFF and histologic response in patients with nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 31, 31220\u201331229 (2020).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"1489_CR34","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1177\/1756283X16656735","volume":"9","author":"J Patel","year":"2016","unstructured":"Patel, J. et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Ther. Adv. Gastroenterol. 9, 692\u2013701 (2016).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"1489_CR35","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1172\/JCI27300","volume":"116","author":"DB Savage","year":"2006","unstructured":"Savage, D. B. et al. Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2. J. Clin. Invest. 116, 817\u2013824 (2006).","journal-title":"J. Clin. Invest."},{"key":"1489_CR36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/cpdd.782","volume":"9","author":"A Bergman","year":"2020","unstructured":"Bergman, A. et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of a liver-targeting ACC inhibitor (PF-05221304): a three-part randomized phase 1 study. Clin. Pharmacol. Drug. Dev. 9, 514\u2013526 (2020).","journal-title":"Clin. Pharmacol. Drug. Dev."},{"key":"1489_CR37","unstructured":"Lawitz, E. J. et al. Fenofibrate mitigates increases in serum triglycerides due to the ACC inhibitor firsocostat in patients with advanced fibrosis due to NASH: a phase 2 randomized trial. American Association for the Study of Liver Diseases meeting, Boston, MA, USA (2019)."},{"key":"1489_CR38","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1210\/jc.2009-2622","volume":"95","author":"E Fabbrini","year":"2010","unstructured":"Fabbrini, E. et al. Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 95, 2727\u20132735 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1489_CR39","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1016\/j.jacl.2018.08.003","volume":"12","author":"J Oscarsson","year":"2018","unstructured":"Oscarsson, J. et al. Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease: a double-blind, randomized, placebo-controlled study. J. Clin. Lipido. 12, 1390\u20131403 (2018).","journal-title":"J. Clin. Lipido."},{"key":"1489_CR40","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/nu11020475","volume":"11","author":"HM Parker","year":"2019","unstructured":"Parker, H. M. et al. Effect of fish oil supplementation on hepatic and visceral fat in overweight men: a randomized controlled trial. Nutrients 11, 475 (2019).","journal-title":"Nutrients"},{"key":"1489_CR41","doi-asserted-by":"crossref","first-page":"e005549","DOI":"10.1161\/JAHA.117.005549","volume":"6","author":"PR Lawler","year":"2017","unstructured":"Lawler, P. R. et al. Atherogenic lipoprotein determinants of cardiovascular disease and residual risk among individuals with low low-density lipoprotein cholesterol. J. Am. Heart Assoc. 6, e005549 (2017).","journal-title":"J. Am. Heart Assoc."},{"key":"1489_CR42","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1161\/CIRCULATIONAHA.115.016857","volume":"132","author":"S Mora","year":"2015","unstructured":"Mora, S. et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: the justification for the use of statins in prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circulation 132, 2220\u20132229 (2015).","journal-title":"Circulation"},{"key":"1489_CR43","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1172\/JCI127308","volume":"129","author":"JE Kanter","year":"2019","unstructured":"Kanter, J. E. et al. Increased apolipoprotein C3 drives cardiovascular risk in type 1 diabetes. J. Clin. Invest. 129, 4165\u20134179 (2019).","journal-title":"J. Clin. Invest."},{"key":"1489_CR44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0006-291X(72)80149-9","volume":"46","author":"WV Brown","year":"1972","unstructured":"Brown, W. V. & Baginsky, M. L. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem. Biophys. Res. Commun. 46, 375\u2013382 (1972).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"1489_CR45","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1172\/JCI112713","volume":"78","author":"HN Ginsberg","year":"1986","unstructured":"Ginsberg, H. N. et al. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78, 1287\u20131295 (1986).","journal-title":"J. Clin. Invest."},{"key":"1489_CR46","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1172\/JCI111711","volume":"75","author":"CS Wang","year":"1985","unstructured":"Wang, C. S., McConathy, W. J., Kloer, H. U. & Alaupovic, P. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III. J. Clin. Invest. 75, 384\u2013390 (1985).","journal-title":"J. Clin. Invest."},{"key":"1489_CR47","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/hep.21655","volume":"45","author":"K Yamaguchi","year":"2007","unstructured":"Yamaguchi, K. et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366\u20131374 (2007).","journal-title":"Hepatology"},{"key":"1489_CR48","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.30765","volume":"70","author":"NL Gluchowski","year":"2019","unstructured":"Gluchowski, N. L. et al. Hepatocyte deletion of triglyceride-synthesis enzyme acyl CoA: diacylglycerol acyltransferase 2 reduces steatosis without increasing inflammation or fibrosis in mice. Hepatology 70, 1972\u20131985 (2019).","journal-title":"Hepatology"},{"key":"1489_CR49","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/hep.25731","volume":"56","author":"TA Le","year":"2012","unstructured":"Le, T. A. et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56, 922\u2013932 (2012).","journal-title":"Hepatology"},{"key":"1489_CR50","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1002\/hep.27647","volume":"61","author":"R Loomba","year":"2015","unstructured":"Loomba, R. et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61, 1239\u20131250 (2015).","journal-title":"Hepatology"},{"key":"1489_CR51","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.29797","volume":"68","author":"C Caussy","year":"2018","unstructured":"Caussy, C., Reeder, S. B., Sirlin, C. B. & Loomba, R. Noninvasive, quantitative assessment of liver fat by MRI\u2013PDFF as an endpoint in NASH trials. Hepatology 68, 763\u2013772 (2018).","journal-title":"Hepatology"},{"key":"1489_CR52","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/jmri.23928","volume":"37","author":"A Mashhood","year":"2013","unstructured":"Mashhood, A. et al. Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging. J. Magn. Reson. Imaging 37, 1359\u20131370 (2013).","journal-title":"J. Magn. Reson. Imaging"}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01489-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01489-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T20:06:35Z","timestamp":1673467595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-021-01489-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1038\/s41591-021-01489-1","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"11 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.A.C., N. Amin, S.C.-G., T.T.R., A.B., S.A., C.C., A.R., J.M., V.S.,T.A.T., K.K., M.B., G.T., R.D., K.K.B., A.M.K., J.A.P. and W.P.E. are employees of, and might hold stock options in, Pfizer Inc. N. Aggarwal and M.I. have no conflicts of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}